Civica Rx To Manufacture & Distribute Affordable Insulin

Civica Rx plans to manufacture and distribute three types of insulin that would have a consumer price point of no more than $30 per vial, and no more than $55 for a box of five pen cartridges. Both of these prices are lower than current market prices for insulin. Civica Rx plans to produce three insulins – glargine, lispro, and aspart (biologics corresponding to, and interchangeable with, Lantus, Humalog and Novolog respectively). Commercial sales are anticipated to launch in 2024. The Blue Cross Blue Shield (BCBS) Association and 12 independent BCBS companies have agreed to cover the Civica Rx insulin.

To . . .